ATXI:NSD-Avenue Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 4.54

Change

-0.11 (-2.37)%

Market Cap

USD 0.08B

Volume

0.31M

Average Target Price

USD 6.00 (+32.16%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was incorporated in 2015 and is based in New York, New York.

Company Website : http://www.avenuetx.com

Address : 1140 Avenue of the America, New York, NY, United States, 10036

Employees : 4

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 0.75

52 Week High : 12.34

Short Ratio : 1.85

52 Week Low : 2.85

Shorted Shares : 448,687

200 Day Moving Average : 5.54

Shorted Shares Previous Month : 402,514

50 Day Moving Average : 6.07

Shares Held By Insiders : 602.95%

Short Percentage : 3.00%

Shares Held by Institutions : 12.33%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+10.94 (+6.84%)

 USD64.03B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

-1.71 (-0.77%)

 USD57.23B 21.49 15.27
REGN Regeneron Pharmaceuticals, Inc

+7.96 (+1.61%)

 USD51.55B 15.77 12.24
ALXN Alexion Pharmaceuticals, Inc

+6.14 (+3.90%)

 USD34.80B 57.92 33.71
BNTX BioNTech SE

+10.82 (+7.69%)

 USD33.39B -99,999.99 N/A
BGNE BeiGene, Ltd

-2.27 (-0.74%)

 USD27.77B N/A N/A
SGEN Seagen Inc

-4.14 (-2.77%)

 USD27.13B 44.40 34.88
RPRX Royalty Pharma plc

+0.22 (+0.53%)

 USD25.29B 22.60 15.33
GMAB Genmab A/S

+0.25 (+0.71%)

 USD22.79B 26.59 3.26
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A

ETFs Containing ATXI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -23.70% 20% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.70% 20% F 10% F
Trailing 12 Months  
Capital Gain -51.75% 7% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -51.75% 7% F 3% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 20.32% 55% F 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.32% 55% F 70% C-
Risk Return Profile  
Volatility (Standard Deviation) 45.68% 69% D+ 37% F
Risk Adjusted Return 44.48% 71% C- 66% D
Market Capitalization 0.08B 14% F 17% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 38.48 3% F 3% F
Price / Cash Flow Ratio -16,882.43 100% A+ 100% A+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -112.48% 24% F 10% F
Return on Invested Capital -0.11% 85% B 50% F
Return on Assets -53.59% 13% F 4% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.85 65% D 56% F
Short Percent 6.76% 48% F 31% F
Beta 0.75 79% C+ 76% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.